This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Stock Roundup: Trump, Pharma Executives Meeting on Coronavirus, FDA Updates
by Kinjel Shah
Trump asks pharma firms to accelerate development of coronavirus vaccine/treatment. FDA approves Sanofi's (SNY) Sarclisa and Allergan'sa (AGN) Durysta.
The Zacks Analyst Blog Highlights: Walmart, Pfizer, Charter Communications, Lockheed Martin and CME
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Walmart, Pfizer, Charter Communications, Lockheed Martin and CME
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Sweta Killa
Sector ETF report for PPH
Top Stock Reports for Walmart, Pfizer & Charter Communications
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Walmart (WMT), Pfizer (PFE) and Charter Communications (CHTR).
Inovio Surges on Expedited Timeline for Coronavirus Vaccine
by Zacks Equity Research
Inovio (INO) to initiate human clinical studies on INO-4800, its DNA vaccine, this April, for the treatment of the deadly coronavirus. The stock price shoots up.
Lilly Expects No Drug Supply Shortages Due to Coronavirus
by Zacks Equity Research
Lilly (LLY) does not expect shortage in supply of its medicines as it does not source APIs of any of its marketed drugs from China.
Sanofi's Sarclisa Gets FDA Nod for Third-Line Multiple Myeloma
by Zacks Equity Research
The FDA approves Sanofi's (SNY) Sarclisa (isatuximab) combo for the treatment of adult patients with relapsed refractory multiple myeloma in the third-line setting.
Roche's Esbriet Gets FDA Breakthrough Tag for New Indication
by Zacks Equity Research
Roche (RHHBY) gets Breakthrough Therapy status from the FDA for Esbriet in adults with unclassifiable interstitial lung disease.
Pfizer Plans Coronavirus Therapy, Progresses With Tanezumab BLA
by Zacks Equity Research
Pfizer (PFE) identifies potential antiviral compounds to develop a treatment for coronavirus disease. The FDA accepts regulatory application seeking approval for tanezumab for osteoarthritis.
Merck's Keytruda Improves PFS in Phase III Lymphoma Study
by Zacks Equity Research
Merck's (MRK) Keytruda significantly improves progression-free survival compared with brentuximab vedotin in patients with relapsed or refractory classical Hodgkin Lymphoma (cHL)
Is the Options Market Predicting a Spike in Pfizer (PFE) Stock?
by Zacks Equity Research
Investors need to pay close attention to Pfizer (PFE) stock based on the movements in the options market lately.
Is Pfizer (PFE) Stock a Solid Choice Right Now?
by Zacks Equity Research
Pfizer (PFE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Dow Logs Worst One-Day Slump in History: ETF & Stock Winners
by Sanghamitra Saha
Dow Jones saw the worst single-day slump on Thursday. While inverse Dow Jones ETFs gained considerably, these stocks too were less hurt.
Mylan's (MYL) Q4 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Mylan's (MYL) earnings beat estimates but sales miss the same in the fourth quarter of 2019.
Nektar (NKTR) Q4 Earnings & Revenues Top Estimates, Stock Up
by Zacks Equity Research
Nektar (NKTR) reports encouraging fourth-quarter results. The company continues to progress with its pipeline candidates.
Why Is Pfizer (PFE) Down 7.6% Since Last Earnings Report?
by Zacks Equity Research
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bayer (BAYRY) Q4 Earnings Beat Estimates, Sales Rise Y/Y
by Zacks Equity Research
Bayer (BAYRY) beats earnings estimates in the fourth quarter of 2019.
Exelixis (EXEL) Beats on Earnings, Misses on Sales in Q4
by Zacks Equity Research
Exelixis' (EXEL) Q4 results are a mixed bag, as earnings beat, while sales marginally miss estimates.
Theravance (TBPH) Q4 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Theravance (TBPH) reports earnings miss in the fourth quarter while sales beat estimates.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Bayer Aktiengesellschaft, Pfizer, Mylan N.V. and Teva Pharmaceutical Industries
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Bayer Aktiengesellschaft, Pfizer, Mylan N.V. and Teva Pharmaceutical Industries
Aerie's (AERI) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Aerie (AERI) reports a wider loss in the fourth quarter, while sales surpass expectations.
Pharma Stock Roundup: AZN Reports Q4 Results, NVS, PFE Drugs Get EU Approval
by Kinjel Shah
AstraZeneca's (AZN) Q4 results were disappointing. European Commission approves Novartis (NVS) and Pfizer's (PFE) new drugs.
3 Best Drugmakers That Are Immune to Coronavirus Fright
by Manaswita Ghosh Dutta
The global reliance on China for APIs and drug manufacturing might hit supply chains and production amid the Coronavirus outbreak. Thus, companies independent of China's input are up for grabs now.
Pfizer's Cardiomyopathy Drug Vyndaqel Gets Approval in Europe
by Zacks Equity Research
Pfizer's (PFE) Vyndaqel gets approval in Europe and becomes the first therapy approved to treat ATTR-CM in the continent.
Glaxo Underperforms Industry in a Year: What's in Store?
by Zacks Equity Research
Shares of Glaxo (GSK) lag the industry in a year as generic erosion of some drugs mainly its top-selling drug, Advair offsets strong sales of new drugs.